The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic researchSyngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced a strategic collaboration with Johns Hopkins University, MD, U.S., to advance early-stage drug discovery programs and platform
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug
Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26. Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins) Q2 FY25Q2 FY26YoY Change (%)Revenue from Operations8919112%Reported Revenue9089262%Reported EBITDA261215-18%Reported EBITDA margin (%)28.8%23.2% Reported PAT (before exceptional items)10667-37%Reported PAT Margin (%)11.7%7.3% H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins) H1 FY25H1 FY26YoY Change (%)Revenue from Operations1,6811,7856%Reported Revenue1,7151,8186%Reported EBITDA449439-2%Reported EBITDA margin (%)26.2%24.1% Reported PAT (before exceptional items)161*154-4%Reported PAT Margin (%)9.4%8.5% Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim. Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Our Q2 performance was driven by underlying revenue growth from research
Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies servicesSyngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development servicesSyngene International, a global contract research, development, and manufacturing organization (CRDMO), announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster. The investments included a dedicated, state-of-the-art
40 women from tier two and three institutions selected for the third cohort of the program Over 50 women benefitted from the successful conclusion of the first and second cohortSyngene International Ltd., an integrated research, development, and manufacturing services organization, in partnership with
Syngene International Limited today announced that Jonathan Hunt has stepped down from his role as MD & CEO as well as from the Board of Directors to pursue other opportunities in due course. Consequent to this, the Board has appointed Peter Bains as the CEO
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 croresSyngene International Limited today announced its third quarter financial results. Reported revenue from operations was up by 11% year-on-year to Rs. 944
Revenue from operations increased sequentially by 13% to Rs. 891 crores, down 2% year-on-year First half FY25 revenue was broadly flat, in line with our guidance, at Rs. 1,681 croresSyngene International Limited today announced its second quarter and half year financial results. Revenue from
Full-year revenue from operations up 9% to Rs 3,489 Cr, PAT1 up 12% to Rs 519 Cr Fourth quarter revenue from operations declined 8% year-on-year to Rs. 917 Cr, PAT1 increased 6% to Rs. 189 CrSyngene International Limited today announced its full-year
